Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Phase 2

Completed

Conditions: Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer
Estrogen Receptor Negative (ER-Negative) Breast Cancer
Progesterone Receptor Negative (PR-Negative) Breast Cancer
Brain Metastases

Interventions: Drug: INIPARIB + irinotecan

First Posted Date: 2010-08-02

Last Posted Date: 2016-03-17

Lead Sponsor: Sanofi

Target Recruit Count: 44

Registration Number: NCT01173497

Locations: 🇺🇸
University of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 10 locations

Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Lixisenatide (AVE0010)
Drug: Placebo
Device: Pen auto-injector
Drug: Metformin
Drug: Sulfonylurea

First Posted Date: 2010-07-26

Last Posted Date: 2016-10-13

Lead Sponsor: Sanofi

Target Recruit Count: 391

Registration Number: NCT01169779

Locations: 🇨🇳
Investigational Site Number 156009, Beijing, China
🇨🇳
Investigational Site Number 156016, Changsha, China
🇨🇳
Investigational Site Number 156015, Changsha, China

and more 32 locations

Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine

First Posted Date: 2010-07-26

Last Posted Date: 2013-07-08

Lead Sponsor: Sanofi

Target Recruit Count: 555

Registration Number: NCT01169818

Locations: 🇷🇺
Administrative office, Moscow, Russian Federation

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Iniparib

First Posted Date: 2010-07-14

Last Posted Date: 2013-09-24

Lead Sponsor: Sanofi

Target Recruit Count: 7

Registration Number: NCT01161836

Locations: 🇺🇸
Northwest Medical Specialties, Tacoma, Washington, United States

Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin glulisine
Drug: Insulin aspart

First Posted Date: 2010-07-09

Last Posted Date: 2010-07-16

Lead Sponsor: Sanofi

Target Recruit Count: 37

Registration Number: NCT01159353

Locations: 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France

Dermacyd in Odor Reducing.

Phase 3

Completed

Conditions: Hygiene

Interventions: Drug: LACTIC ACID (Dermacid)
Drug: Glycerine Vegetal Soap Granado Traditional

First Posted Date: 2010-07-08

Last Posted Date: 2011-01-04

Lead Sponsor: Sanofi

Target Recruit Count: 230

Registration Number: NCT01158365

Locations: 🇧🇷
Sanofi-Aventis Investigational Site Number 076-001, Osasco, Brazil

Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication

Phase 2

Completed

Conditions: Peripheral Arterial Occlusive Disease

Interventions: Drug: placebo
Drug: XRP0038 (NV1FGF)

First Posted Date: 2010-07-07

Last Posted Date: 2010-07-07

Lead Sponsor: Sanofi

Target Recruit Count: 36

Registration Number: NCT01157871

First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor

Phase 1

Completed

Conditions: Neoplasm Malignant

Interventions: Drug: SAR566658

First Posted Date: 2010-07-05

Last Posted Date: 2017-05-10

Lead Sponsor: Sanofi

Target Recruit Count: 114

Registration Number: NCT01156870

Locations: 🇺🇸
Investigational Site Number 840002, Cincinnati, Ohio, United States
🇫🇷
Investigational Site Number 250001, Toulouse Cedex, France
🇺🇸
Investigational Site Number 840001, San Antonio, Texas, United States

and more 2 locations